ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CFO Mark C. Schneyer Sells 10,259 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CFO Mark C. Schneyer sold 10,259 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the completion of the transaction, the chief financial officer now owns 53,302 shares in the company, valued at $896,006.62. The trade was a 16.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

ACADIA Pharmaceuticals Price Performance

Shares of ACADIA Pharmaceuticals stock traded down $0.82 on Tuesday, reaching $16.21. The company had a trading volume of 1,562,268 shares, compared to its average volume of 1,681,843. The firm has a market cap of $2.70 billion, a price-to-earnings ratio of 20.78 and a beta of 0.38. The firm’s 50-day moving average price is $15.60 and its two-hundred day moving average price is $15.99. ACADIA Pharmaceuticals Inc. has a 1 year low of $14.15 and a 1 year high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.06. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The business had revenue of $250.40 million for the quarter, compared to the consensus estimate of $248.83 million. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. The business’s revenue for the quarter was up 18.3% on a year-over-year basis. As a group, analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.72 EPS for the current year.

Analysts Set New Price Targets

ACAD has been the topic of a number of recent research reports. StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Raymond James reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 10th. Royal Bank of Canada reduced their target price on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Citigroup lowered their price target on shares of ACADIA Pharmaceuticals from $30.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Finally, UBS Group reduced their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Six investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.56.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several hedge funds have recently bought and sold shares of ACAD. Park Place Capital Corp bought a new position in shares of ACADIA Pharmaceuticals in the third quarter worth about $25,000. Values First Advisors Inc. purchased a new position in shares of ACADIA Pharmaceuticals during the third quarter worth approximately $27,000. Covestor Ltd raised its stake in shares of ACADIA Pharmaceuticals by 70.5% during the first quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 840 shares in the last quarter. Quest Partners LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 1,047 shares during the period. Finally, Stonepine Capital Management LLC bought a new position in ACADIA Pharmaceuticals in the second quarter worth approximately $81,000. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.